Drug interactions in the therapy of malignant diseases:
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | German |
| Veröffentlicht: |
München [u.a.]
Zuckschwerdt
1995
|
| Ausgabe: | 3. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Dt. Ausg. u.d.T.: Illiger, Hans J.: Arzneimittelinteraktionen bei der Therapie maligner Erkrankungen |
| Beschreibung: | XLIII, 160 S. Ill. |
| ISBN: | 3886035395 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV010432237 | ||
| 003 | DE-604 | ||
| 005 | 19960102 | ||
| 007 | t | ||
| 008 | 951002s1995 gw a||| |||| 00||| ger d | ||
| 016 | 7 | |a 945677367 |2 DE-101 | |
| 020 | |a 3886035395 |c Pb. : DM 39.00, sfr 39.00, S 305.00 |9 3-88603-539-5 | ||
| 035 | |a (OCoLC)39143446 | ||
| 035 | |a (DE-599)BVBBV010432237 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a ger | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-12 |a DE-19 | ||
| 100 | 1 | |a Illiger, Hans J. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Drug interactions in the therapy of malignant diseases |c H. J. Illiger ; L. Bornmann ; K. Herdrich |
| 250 | |a 3. ed. | ||
| 264 | 1 | |a München [u.a.] |b Zuckschwerdt |c 1995 | |
| 300 | |a XLIII, 160 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Dt. Ausg. u.d.T.: Illiger, Hans J.: Arzneimittelinteraktionen bei der Therapie maligner Erkrankungen | ||
| 650 | 7 | |a Chimiothérapie - Complications |2 ram | |
| 650 | 2 | |a Chimiothérapie - Effets indésirables | |
| 650 | 2 | |a Interactions médicamenteuses - Manuel | |
| 650 | 2 | |a Tumeurs - Chimiothérapie | |
| 650 | 4 | |a Drug Interactions |v handbooks | |
| 650 | 4 | |a Drug Therapy |x adverse effects |v handbooks | |
| 650 | 4 | |a Neoplasms |x drug therapy |v handbooks | |
| 650 | 0 | 7 | |a Pharmakokinetik |0 (DE-588)4115557-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapeutikum |0 (DE-588)4009895-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | 2 | |a Pharmakokinetik |0 (DE-588)4115557-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Chemotherapeutikum |0 (DE-588)4009895-3 |D s |
| 689 | 1 | 2 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 2 | 1 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 2 | 2 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 3 | 1 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 3 | |5 DE-604 | |
| 689 | 4 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 4 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 4 | 2 | |a Arzneimittelwechselwirkung |0 (DE-588)4003147-0 |D s |
| 689 | 4 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Bornmann, Lothar |e Verfasser |4 aut | |
| 700 | 1 | |a Herdrich, Klaus |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006951952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-006951952 | |
Datensatz im Suchindex
| _version_ | 1807505732717772800 |
|---|---|
| adam_text |
TABLE
OF
CONTENTS
INTRODUCTION
.
XIX
AMINOGLUTETHIMIDE
.
1
AMINOGLUTETHIMIDE
AND
ANTIPYRINE
.
1
AMMOGLUTETHIMIDE
AND
BETA
BLOCKER
.
1
AMMOGLUTETHIMIDE
AND
DEXAMETHASONE
.
1
AMINOGLUTETHIMIDE
AND
DIGITOXIN
.
1
AMINOGLUTETHIMIDE
AND
DIURETICS
.
1
AMINOGLUTETHIMIDE
AND
MEDROXYPROGESTERONE
ACETATE
AMMOGLUTETHIMIDE
AND
MEGESTROL
ACETATE
.
AMINOGLUTETHIMIDE
AND
OESTROGENS
.
AMINOGLUTETHIMIDE
AND
TAMOXIFEN
.
AMINOGLUTETHIMIDE
AND
THEOPHYLLINE
.
AMINOGLUTETHIMIDE
AND
WARFARIN
.
ASPARAGINASE
.
ASPARAGINASE
AND
ANTIDIABETICS
.
ASPARAGINASE
AND
ETOPOSIDE
.
ASPARAGINASE
AND
VINCRISTINE
.
AZATHIOPRINE
.
AZATHIOPRINE
AND
ALLOPURINOL
.
AZATHIOPRINE
AND
ANGIOTENSIN-CONVERTING
ENZYME
(ACE)
INHIBITORS
.
AZATHIOPRINE
AND
CYCLOPHOSPHAMIDE
.
AZATHIOPRINE
AND
CYCLOSPORINE
.
AZATHIOPRINE
AND
NEUROMUSCULAR
BLOCKING
AGENTS
.
AZATHIOPRINE
AND
TRIMETHOPRIM
.
AZATHIOPRINE
AND
WARFARIN
.
BLEOMYCIN
.
BLEOMYCIN
AND
ACETYLDIGOXIN
.
BLEOMYCIN
AND
CISPLATINUM
.
BLEOMYCIN
AND
OXYGEN
/
NITROUS
OXIDE
.
BLEOMYCIN
AND
PHENYTOIN
.
CM
CM
CM
CM
CM
CM
10
10
10
IO
IO
CO
CO
CD
CO
CO
CO
CO
CO
BUSULFAN
.
10
BUSULFAN
AND
PHENYTOIN
.
10
CARBOPLATIN
.
11
CARBOPLATIN
AND
AMINOGLYCOSIDE
ANTIBIOTICS
.
11
CARBOPLATIN
AND
ETOPOSIDE
.
11
CARBOPLATIN
AND
IFOSFAMIDE
.
11
CARBOPLATIN
AND
PHENYTOIN
.
11
CARBOPLATIN
AND
SODIUM
THIOSULFATE
.
11
CARMUSTINE
(BCNU)
.
13
CARMUSTINE
AND
AMPHOTERICIN
B
.
13
CARMUSTINE
AND
CIMETIDINE
.
13
CARMUSTINE
AND
MELPHALAN
.
13
CARMUSTINE
AND
PHENOBARBITAL
.
13
CARMUSTINE
AND
PHENYTOIN
.
13
CHLORAMBUCIL
.
16
CHLORAMBUCIL
AND
CYCLOSPORINE
.
16
CHLORAMBUCIL
AND
FOOD
.
16
CHLORAMBUCIL
AND
ORAL
POLIO
VACCINATION
(OPV)
.
16
CHLOROZOTOCIN
.
17
CHLOROZOTOCIN
AND
MITOMYCIN
C
.
17
CISPLATINUM
.
18
CISPLATINUM
AND
AMINOGLYCOSIDE
.
18
CISPLATINUM
AND
ANTICONVULSANT
DRUGS
.
18
CISPLATINUM
AND
BLEOMYCIN
.
18
CISPLATINUM
AND
CYCLOPHOSPHAMIDE
.
18
CISPLATINUM
AND
DIPYRIDAMOLE
.
19
CISPLATINUM
AND
DOMPERIDON
.
19
CISPLATINUM
AND
DOXORUBICIN
.
19
CISPLATINUM
AND
DROPERIDOL
.
19
CISPLATINUM
AND
ETHACRYNIC
ACID
.
20
CISPLATINUM
AND
ETOPOSIDE
.
20
CISPLATINUM
AND
FLUOROURACIL
.
20
CISPLATINUM
AND
FUROSEMIDE
.
20
CISPLATINUM
AND
IFOSFAMIDE
.
20
CISPLATINUM
AND
LNTERLEUKIN-2
.
21
CISPLATINUM
AND
IRRADIATION
.
21
CISPLATINUM
AND
LITHIUM
.
21
VI
CISPLATINUM
AND
MELPHALAN
.
21
CISPLATINUM
AND
METHOTREXATE
.
21
CISPLATINUM
AND
METOCLOPRAMIDE
.
22
CISPLATINUM
AND
NAVELBINE
(VINORELBINE)
.
22
CISPLATINUM
AND
SELEN-COMPOUNDS
.
22
CISPLATINUM
AND
STREPTOZOTOCIN
.
23
CISPLATINUM
AND
THIOLS
.
23
CISPLATINUM
AND
TRIMETHOPRIM
I
SULFADIAZINE
.
23
CISPLATINUM
AND
VINBLASTINE
.
24
CYCLOPHOSPHAMIDE
.
29
CYCLOPHOSPHAMIDE
AND
ALLOPURINOL
.
29
CYCLOPHOSPHAMIDE
AND
ANTIDIABETICS
.
29
CYCLOPHOSPHAMIDE
AND
AZATHIOPRINE
.
29
CYCLOPHOSPHAMIDE
AND
BENZODIAZEPINES
.
29
CYCLOPHOSPHAMIDE
AND
CHLORAMPHENICOL
.
30
CYCLOPHOSPHAMIDE
AND
CHLOROQUINE
.
30
CYCLOPHOSPHAMIDE
AND
CHLORPROMAZINE
OR
TRIIODOTHYRONINE
.
30
CYCLOPHOSPHAMIDE
AND
CIMETIDINE
.
30
CYCLOPHOSPHAMIDE
AND
CISPLATINUM
.
31
CYCLOPHOSPHAMIDE
AND
CORTICOSTEROIDS
.
31
CYCLOPHOSPHAMIDE
AND
CYTARABINE
.
31
CYCLOPHOSPHAMIDE
AND
DAPSONE
.
31
CYCLOPHOSPHAMIDE
AND
DIGOXIN
.
32
CYCLOPHOSPHAMIDE
AND
DIURETICS
.
32
CYCLOPHOSPHAMIDE
AND
DOXORUBICIN
.
32
CYCLOPHOSPHAMIDE
AND
ETOPOSIDE
.
33
CYCLOPHOSPHAMIDE
AND
FAMOTIDINE
.
33
CYCLOPHOSPHAMIDE
AND
FLUOROURACIL
.
33
CYCLOPHOSPHAMIDE
AND
HALOTHANE
.
33
CYCLOPHOSPHAMIDE
AND
INDOMETHACIN
.
34
CYCLOPHOSPHAMIDE
AND
IRRADIATION
.
34
CYCLOPHOSPHAMIDE
AND
LEVONANTRADOL
.
34
CYCLOPHOSPHAMIDE
AND
MESNA
.
34
CYCLOPHOSPHAMIDE
AND
MORPHINE
.
34
CYCLOPHOSPHAMIDE
AND
NIFEDIPINE
.
35
CYCLOPHOSPHAMIDE
AND
PENTOSTATIN
.
35
CYCLOPHOSPHAMIDE
AND
PETHIDINE
.
35
CYCLOPHOSPHAMIDE
AND
PHENOBARBITAL
.
35
VII
CYCLOPHOSPHAMIDE
AND
PREDNISONE
.
36
CYCLOPHOSPHAMIDE
AND
PROCARBAZINE
.
36
CYCLOPHOSPHAMIDE
AND
RANITIDINE
.
36
CYCLOPHOSPHAMIDE
AND
SUXAMETHONIUM
.
37
CYCLOPHOSPHAMIDE
AND
TAMOXIFEN
.
37
CYCLOPHOSPHAMIDE
AND
VACCINES
.
37
CYCLOSPORINE
.
44
CYCLOSPORINE
AND
ALLOPURINOL
.
44
CYCLOSPORINE
AND
AMIODARONE
.
44
CYCLOSPORINE
AND
AZATHIOPRINE
.
44
CYCLOSPORINE
AND
CARBAMAZEPINE
.
44
CYCLOSPORINE
AND
CEFTRIAXONE
.
44
CYCLOSPORINE
AND
CHLORAMBUCIL
.
45
CYCLOSPORINE
AND
CHLOROQUINE
.
45
CYCLOSPORINE
AND
CIPROFLOXACIN
.
45
CYCLOSPORINE
AND
CYTARABINE
.
45
CYCLOSPORINE
AND
DANAZOL
.
45
CYCLOSPORINE
AND
DAUNORUBICIN
.
45
CYCLOSPORINE
AND
DICLOFENAC
.
46
CYCLOSPORINE
AND
DILTIAZEM
.
46
CYCLOSPORINE
AND
DOXORUBICIN
.
46
CYCLOSPORINE
AND
ETOPOSIDE
.
47
CYCLOSPORINE
AND
FLUCONAZOLE
.
47
CYCLOSPORINE
AND
GLIPIZIDE
.
47
CYCLOSPORINE
AND
GRISEOFULVIN
.
47
CYCLOSPORINE
AND
ITRACONAZOLE
.
47
CYCLOSPORINE
AND
JOSAMYCIN
.
48
CYCLOSPORINE
AND
KETOCONAZOLE
.
48
CYCLOSPORINE
AND
MELPHALAN
.
48
CYCLOSPORINE
AND
METHOTREXATE
.
48
CYCLOSPORINE
AND
NONSTEROIDAL
ANTIINFLAMMATORY
DRUGS
.
48
CYCLOSPORINE
AND
OMEPRAZOLE
.
49
CYCLOSPORINE
AND
PROPAFENONE
.
49
CYCLOSPORINE
AND
QUININE
.
49
CYCLOSPORINE
AND
RIFAMPICIN
.
49
CYCLOSPORINE
AND
SULFADIAZINE
.
49
CYCLOSPORINE
AND
VINCRISTINE
.
49
VIII
CYTARABINE
.
55
CYTARABINE
AND
AMPHOTERICIN
B
.
55
CYTARABINE
AND
CYCLOPHOSPHAMIDE
.
55
CYTARABINE
AND
CYCLOSPORINE
.
55
CYTARABINE
AND
DIPYRIDAMOLE
.
55
CYTARABINE
AND
ETOPOSIDE
.
55
CYTARABINE
AND
FLUCYTOSINE
.
56
CYTARABINE
AND
FLUDARABINE
.
56
CYTARABINE
AND
HYDROXYUREA
.
56
CYTARABINE
AND
IDARUBICIN
.
56
CYTARABINE
AND
TENIPOSIDE
.
56
CYTARABINE
AND
THYMIDINE
.
57
DACARBAZINE
.
59
DACARBAZINE
AND
DOXORUBICIN
.
59
DACARBAZINE
AND
FOTEMUSTINE
.
59
DACARBAZINE
AND
LNTERLEUKIN-2
.
59
DACARBAZINE
AND
LEVODOPA
.
59
DACTINOMYCIN
.
61
DACTINOMYCIN
AND
VINCRISTINE
.
61
DAUNORUBICIN
.
62
DAUNORUBICIN
AND
CYCLOSPORINE
.
62
DAUNORUBICIN
AND
CYTARABINE,
THIOGUANINE,
PYRIMETHAMINE
.
62
DAUNORUBICIN
AND
ICRF-187
.
62
DAUNORUBICIN
AND
VERAPAMIL
.
62
DOXORUBICIN
.
64
DOXORUBICIN
AND
ANTICONVULSANT
DRUGS
.
64
DOXORUBICIN
AND
CIMETIDINE
.
64
DOXORUBICIN
AND
CISPLATINUM
.
64
DOXORUBICIN
AND
CYCLOPHOSPHAMIDE
.
64
DOXORUBICIN
AND
CYCLOSPORINE
.
64
DOXORUBICIN
AND
OTHER
CYTOTOXIC
AGENTS,
RADIOTHERAPY
.
64
DOXORUBICIN
AND
DIGITALIS
.
65
DOXORUBICIN
AND
DIPYRIDAMOLE
.
65
DOXORUBICIN
AND
ETOPOSIDE
.
65
DOXORUBICIN
AND
ICRF-187
.
65
IX
DOXORUBICIN
AND
M-AMSA
.
66
DOXORUBICIN
AND
MELPHALAN
.
66
DOXORUBICIN
AND
MERCAPTOPURINE
.
66
DOXORUBICIN
AND
MITOMYCIN
C
.
66
DOXORUBICIN
AND
PACLITAXEL
.
66
DOXORUBICIN
AND
PHENOBARBITAL
.
66
DOXORUBICIN
AND
PROPRANOLOL
.
66
DOXORUBICIN
AND
STREPTOZOTOCIN
.
66
DOXORUBICIN
AND
SUPEROXIDE
DISMUTASE
.
67
DOXORUBICIN
AND
TAMOXIFEN
.
67
DOXORUBICIN
AND
VERAPAMIL
.
67
EPIRUBICIN
.
70
EPIRUBICIN
AND
INTERFERON
.
70
EPIRUBICIN
AND
QUININE
.
70
EPIRUBICIN
AND
VERAPAMIL
.
70
ESTRAMUSTINE
.
71
ESTRAMUSTINE
AND
FOOD
.
71
ETOPOSIDE
.
72
ETOPOSIDE
AND
ANTICONVULSANTS
.
72
ETOPOSIDE
AND
ASPARAGINASE
.
72
ETOPOSIDE
AND
CARBOPLATIN
.
72
ETOPOSIDE
AND
CISPLATINUM
.
72
ETOPOSIDE
AND
CYCLOPHOSPHAMIDE
.
72
ETOPOSIDE
AND
CYCLOSPORINE
.
72
ETOPOSIDE
AND
CYTARABINE
.
73
ETOPOSIDE
AND
DIPYRIDAMOLE
.
73
ETOPOSIDE
AND
DOXORUBICIN
.
73
ETOPOSIDE
AND
FOOD
.
73
ETOPOSIDE
AND
IFOSFAMIDE
.
73
ETOPOSIDE
AND
METHOTREXATE
.
73
ETOPOSIDE
AND
NIFEDIPINE
.
74
ETOPOSIDE
AND
PLASMA
PROTEINS
.
74
ETOPOSIDE
AND
SALICYLATE
.
74
ETOPOSIDE
AND
SDZ
PSC
833
.
74
ETOPOSIDE
AND
VINCRISTINE
.
74
ETOPOSIDE
AND
WARFARIN
.
75
X
FLUDARABINE
.
77
FLUDARABINE
AND
CYTARABINE
.
77
FLUOROURACIL
.
78
FLUOROURACIL
AND
ALLOPURINOL
.
78
FLUOROURACIL
AND
ANTIMICROBIAL
DRUGS
.
78
FLUOROURACIL
AND
CALCIUM
FOLINATE
.
78
FLUOROURACIL
AND
CIMETIDINE
.
78
FLUOROURACIL
AND
CISPLATINUM
.
79
FLUOROURACIL
AND
CYCLOPHOSPHAMIDE
.
79
FLUOROURACIL
AND
CYSTEINE
.
79
FLUOROURACIL
AND
DIPYRIDAMOLE
.
79
FLUOROURACIL
AND
FOOD
.
79
FLUOROURACIL
AND
HYDROXYUREA
.
79
FLUOROURACIL
AND
INTERFERON
.
80
FLUOROURACIL
AND
LEVAMISOLE
.
80
FLUOROURACIL
AND
METHOTREXATE
.
80
FLUOROURACIL
AND
MORPHINE
.
80
FLUOROURACIL
AND
PYRIDOXINE
.
81
FLUOROURACIL
AND
TAMOXIFEN
.
81
FLUOROURACIL
AND
TAUROMUSTINE
.
81
FLUOROURACIL
AND
WARFARIN
.
81
FOSFESTROL
.
85
FOTEMUSTINE
.
86
FOTEMUSTINE
AND
DACARBAZINE
.
86
HEXAMETHYLMELAMINE
.
87
HEXAMETHYLMELAMINE
AND
ANTIDEPRESSANTS
.
87
HEXAMETHYLMELAMINE
AND
CIMETIDINE
.
87
HEXAMETHYLMELAMINE
AND
MONOAMINOXIDASE
INHIBITORS
.
87
HEXAMETHYLMELAMINE
AND
PHENOBARBITAL
.
87
HYDROXYUREA
.
89
HYDROXYUREA
AND
CYTARABINE
.
89
HYDROXYUREA
AND
FLUOROURACIL
.
89
XI
IDARUBICIN
.
90
IDARUBICIN
AND
CYTARABINE
.
90
IFOSFAMIDE
.
91
IFOSFAMIDE
AND
CARBOPLATIN
OR
CISPLATINUM
.
91
IFOSFAMIDE
AND
CLOFIBRATE
.
91
IFOSFAMIDE
AND
DEXAMETHASONE
.
91
IFOSFAMIDE
AND
ETOPOSIDE
.
91
IFOSFAMIDE
AND
MESNA
.
91
IFOSFAMIDE
AND
NARINGENIN
.
91
IFOSFAMIDE
AND
PHENOBARBITAL
.
92
IFOSFAMIDE
AND
RADIATION
.
92
IFOSFAMIDE
AND
TRANQUILIZERS
.
92
IFOSFAMIDE
AND
WARFARIN
.
92
INTERFERON
.
94
INTERFERON
AND
ANTIPYRINE
.
94
INTERFERON
AND
DIPYRIDAMOLE
.
94
INTERFERON
AND
EPIRUBICIN
.
94
INTERFERON
AND
ERYTHROPOIETIN
.
94
INTERFERON
AND
FLUOROURACIL
.
94
INTERFERON
AND
MELPHALAN
.
94
INTERFERON
AND
MORPHINE
.
94
INTERFERON
AND
PARACETAMOL
.
95
INTERFERON
AND
PHENOBARBITAL
.
95
INTERFERON
AND
RADIATION
.
95
INTERFERON
AND
THEOPHYLLINE
.
95
INTERFERON
AND
VINBLASTINE
.
95
INTERLEUKIN
.
98
INTERLEUKIN
AND
CISPLATINUM
.
98
INTERLEUKIN
AND
CONTRAST
MEDIA
.
98
INTERLEUKIN
AND
DACARBAZME
.
98
INTERLEUKIN
AND
DEXAMETHASONE
.
98
LOMUSTINE
(CCNU)
.
100
LOMUSTINE
AND
CIMETIDINE
.
100
LOMUSTINE
AND
MELPHALAN
.
100
LOMUSTINE
AND
PHENOBARBITAL
.
100
XII
LOMUSTINE
AND
RADIATION
SENSITIZER
(BENZNIDAZOLE,
MISONIDAZOLE)
.
100
LOMUSTINE
AND
THEOPHYLLINE
.
100
M-AMSA
(AMSACRINE)
.
102
M-AMSA
AND
DOXORUBICIN
.
102
M-AMSA
AND
METHOTREXATE
.
102
M-AMSA
AND
PHENOBARBITAL
.
102
M-AMSA
AND
WARFARIN
.
102
MECHLORETHAMINE
.
103
MECHLORETHAMINE
AND
MUSCLE
RELAXANTS
.
103
MECHLORETHAMINE
AND
PETHIDINE
.
103
MECHLORETHAMINE
AND
PROCARBAZINE
.
103
MECHLORETHAMINE
AND
THIOLS
.
103
MEDROXYPROGESTERONE
ACETATE
.
105
MEDROXYPROGESTERONE
ACETATE
AND
AMINOGLUTETHIMIDE
.
105
MEDROXYPROGESTERONE
ACETATE
AND
ANTICONVULSANT
DRUGS
.
105
MEDROXYPROGESTERONE
ACETATE
AND
ANTIDEPRESSANTS
(AMITRYPTILINE,
CHLORIMIPRAMINE)
.
105
MEDROXYPROGESTERONE
ACETATE
AND
ANTIPYRINE
.
105
MEDROXYPROGESTERONE
ACETATE
AND
CMF
REGIMEN
.
105
MEDROXYPROGESTERONE
ACETATE
AND
MELPHALAN
.
105
MEDROXYPROGESTERONE
ACETATE
AND
MITOMYCIN
C
AND
VINBLASTINE
.
106
MEDROXYPROGESTERONE
ACETATE
AND
TAMOXIFEN
.
106
MEDROXYPROGESTERONE
ACETATE
AND
THEOPHYLLINE
.
106
MELPHALAN
.
108
MELPHALAN
AND
CIMETIDINE
.
108
MELPHALAN
AND
CISPLATINUM
.
108
MELPHALAN
AND
CYCLOSPORINE
.
108
MELPHALAN
AND
OTHER
CYTOTOXIC
AGENTS
.
108
MELPHALAN
AND
DEXAMETHASONE
.
108
MELPHALAN
AND
FOOD
.
109
MELPHALAN
AND
INTERFERON
.
109
MELPHALAN
AND
MEDROXYPROGESTERONE
ACETATE
.
109
MELPHALAN
AND
PREDNISOLONE
.
109
MELPHALAN
AND
TAMOXIFEN
(OR
TOREMIFEN)
.
109
XIII
MERCAPTOPURINE
.
111
MERCAPTOPURINE
AND
ALLOPURINOL
.
111
MERCAPTOPURINE
AND
COTRIMOXAZOLE
.
111
MERCAPTOPURINE
AND
DOXORUBICIN
.
111
MERCAPTOPURINE
AND
FOOD
.
111
MERCAPTOPURINE
AND
METHOTREXATE
.
112
MERCAPTOPURINE
AND
NUCLEOSIDE
ANALOGUES
.
112
METHOTREXATE
.
114
METHOTREXATE
AND
ALCOHOL
.
114
METHOTREXATE
AND
AMINOPHENAZON
.
114
METHOTREXATE
AND
AMIODARONE
.
114
METHOTREXATE
AND
AMITRYPTILINE
.
114
METHOTREXATE
AND
ANTIBIOTICS
.
114
METHOTREXATE
AND
AZAPROPAZONE
.
115
METHOTREXATE
AND
CISPLATINUM
.
115
METHOTREXATE
AND
CYCLOSPORINE
.
115
METHOTREXATE
AND
ETOPOSIDE,TENIPOSIDE,
CYCLOPHOSPHAMIDE
.
115
METHOTREXATE
AND
ETRETINATE
.
115
METHOTREXATE
AND
FLUOROURACIL
.
115
METHOTREXATE
AND
FOOD
.
116
METHOTREXATE
AND
HYDROCHLOROTHIAZIDE
.
116
METHOTREXATE
AND
M-AMSA
.
116
METHOTREXATE
AND
MERCAPTOPURINE
.
116
METHOTREXATE
AND
NITROUS
OXIDE
.
116
METHOTREXATE
AND
NONSTEROIDAL
ANTIINFLAMMATORY
DRUGS
.
116
-
METHOTREXATE
AND
ASPIRIN
.
117
-
METHOTREXATE
AND
DICLOFENAC
.
117
-
METHOTREXATE
AND
GLAFENINE
.
118
-
METHOTREXATE
AND
IBUPROFEN
.
118
-
METHOTREXATE
AND
INDOMETHACIN
.
118
-
METHOTREXATE
AND
KETOPROFEN
.
118
-
METHOTREXATE
AND
NAPROXEN
.
119
-
METHOTREXATE
AND
PHENYLBUTAZONE
.
119
-
METHOTREXATE
AND
SULINDAC
.
119
METHOTREXATE
AND
OMEPRAZOLE
.
119
METHOTREXATE
AND
PREDNISONE
.
119
METHOTREXATE
AND
PROBENECID
.
120
METHOTREXATE
AND
PROCARBAZINE
.
120
XIV
METHOTREXATE
AND
TRIMETHOPRIM
.
120
METHOTREXATE
AND
VINCRISTINE
OR
VINBLASTINE
.
120
METHOTREXATE
AND
VINDESINE
.
121
MITHRAMYCIN
.
126
MITHRAMYCIN
AND
DIPHOSPHONATES,
CALCITONIN,
GLUCAGON
.
126
MITHRAMYCIN
AND
DOXORUBICIN
.
126
MITOMYCIN
C
.
127
MITOMYCIN
C
AND
ANTIBIOTICS
.
127
MITOMYCIN
C
AND
CHLOROZOTOCIN
.
127
MITOMYCIN
C
AND
DICOUMAROL
.
127
MITOMYCIN
C
AND
DOXORUBICIN
.
127
MITOMYCIN
C
AND
FUROSEMIDE
.
127
MITOMYCIN
C
AND
GLYCYLPRESSIN
.
127
MITOMYCIN
C
AND
MEDROXYPROGESTERONE
ACETATE
.
128
MITOMYCIN
C
AND
PYRIDOXINE
.
128
MITOMYCIN
C
AND
TAMOXIFEN
.
128
MITOMYCIN
C
AND
VINBLASTINE
.
128
MITOXANTRONE
.
130
MITOXANTRONE
AND
CEFTAZIDIM
.
130
MITOXANTRONE
AND
DIPYRIDAMOLE
.
130
MITOXANTRONE
AND
N-ACETYLCYSTEINE
.
130
MITOXANTRONE
AND
TOREMIFEN
.
130
NAVELBINE
(VINORELBINE)
.
132
NAVELBINE
AND
CISPLATINUM
.
132
PACLITAXEL
(TAXOL)
.
133
PACLITAXEL
AND
CIMETIDINE
.
133
PACLITAXEL
AND
DOXORUBICIN
.
133
PACLITAXEL
AND
ERYTHROMYCIN
.
133
PACLITAXEL
AND
FLUCONAZOLE
OR
KETOCONAZOLE
.
133
PACLITAXEL
AND
QUINIDINE
.
133
PACLITAXEL
AND
VITAMIN
A
.
133
PENTOSTATIN
.
135
PENTOSTATIN
AND
CYCLOPHOSPHAMIDE
.
135
XV
PREDNIMUSTINE
.
136
PROCARBAZINE
.
137
PROCARBAZINE
AND
ALCOHOL
.
137
PROCARBAZINE
AND
ALLOPURINOL
.
137
PROCARBAZINE
AND
NARCOTIC
ANALGESICS
.
137
PROCARBAZINE
AND
ANTIDEPRESSANTS
.
137
PROCARBAZINE
AND
ANTIDIABETICS
.
137
PROCARBAZINE
AND
ANTIHISTAMINIC/ANTIMUSCARINIC/ANTI
PARKMSONISM
DRUGS
.
137
PROCARBAZINE
AND
CYCLOPHOSPHAMIDE
.
138
PROCARBAZINE
AND
FOOD
.
138
PROCARBAZINE
AND
MECHLORETHAMINE
.
138
PROCARBAZINE
AND
METHOTREXATE
.
138
PROCARBAZINE
AND
SYMPATHOMIMETICS
.
138
SARGRAMOSTIM
(GM-CSF)
.
140
SARGRAMOSTIM
AND
CORTICOSTEROIDS
.
140
SARGRAMOSTIM
AND
LITHIUM
.
140
SEMUSTINE
(METHYL-CCNU)
.
141
SEMUSTINE
AND
MELPHALAN
.
141
STREPTOZOTOCIN
(STREPTOZOCIN)
.
142
STREPTOZOTOCIN
AND
CISPLATINUM
.
142
STREPTOZOTOCIN
AND
DOXORUBICIN
.
142
TAMOXIFEN
.
143
TAMOXIFEN
AND
ALLOPURINOL
.
143
TAMOXIFEN
AND
AMINOGLUTETHIMIDE
.
143
TAMOXIFEN
AND
CYCLOPHOSPHAMIDE
.
143
TAMOXIFEN
AND
DIGITOXIN
.
143
TAMOXIFEN
AND
DOXORUBICIN
.
143
TAMOXIFEN
AND
FLUOROURACIL
.
144
TAMOXIFEN
AND
MEDROXYPROGESTERON
ACETATE
.
144
TAMOXIFEN
AND
MELPHALAN
.
144
TAMOXIFEN
AND
MITOMYCIN
C
.
144
TAMOXIFEN
AND
RADIATION
.
144
TAMOXIFEN
AND
WARFARIN
.
145
XVI
TAUROMUSTINE
.
147
TAUROMUSTINE
AND
FLUOROURACIL
.
147
TEGAFUR
.
148
TENIPOSIDE
.
149
TENIPOSIDE
AND
ANTICONVULSANTS
.
149
TENIPOSIDE
AND
METHOTREXATE
.
149
TENIPOSIDE
AND
VINCRISTINE
.
149
THIOGUANINE
.
150
THIOGUANINE
AND
DAUNORUBICIN
.
150
TOREMIFEN
.
151
TOREMIFEN
AND
MELPHALAN
.
151
TOREMIFEN
AND
MITOXANTRONE
.
151
TROFOSFAMIDE
.
152
UFT
.
153
UFT
AND
PHENYTOIN
.
153
VINBLASTINE
.
154
VINBLASTINE
AND
INTERFERON
.
154
VINBLASTINE
AND
MEDROXYPROGESTERONE
ACETATE
.
154
VINBLASTINE
AND
METHOTREXATE
.
154
VINBLASTINE
AND
MITOMYCIN
C,
CISPLATINUM
.
154
VINBLASTINE
AND
PHENYTOIN
.
154
VINBLASTINE
AND
RADIATION
.
154
VINCRISTINE
.
156
VINCRISTINE
AND
ACETYLDIGOXIN
.
156
VINCRISTINE
AND
ASPARAGINASE
.
156
VINCRISTINE
AND
CYCLOSPORINE
.
156
VINCRISTINE
AND
ETOPOSIDE
.
156
VINCRISTINE
AND
IRRADIATION
.
156
VINCRISTINE
AND
ISONIAZID
.
156
VINCRISTINE
AND
MELPHALAN
.
157
VINCRISTINE
AND
METHOTREXATE
.
157
XVII
VINCRISTINE
AND
METRONIDAZOL
.
157
VINCRISTINE
AND
NIFEDIPINE
.
157
VINCRISTINE
AND
STEROID
HORMONES
.
157
VINCRISTINE
AND
TEMPOSIDE
.
157
VINCRISTINE
AND
VERAPAMIL
.
158
VINDESINE
.
160
VINDESINE
AND
METHOTREXATE
.
160
VINDESINE
AND
MITOMYCIN
C
.
160
VINDESINE
AND
WARFARIN
.
160 |
| any_adam_object | 1 |
| author | Illiger, Hans J. Bornmann, Lothar Herdrich, Klaus |
| author_facet | Illiger, Hans J. Bornmann, Lothar Herdrich, Klaus |
| author_role | aut aut aut |
| author_sort | Illiger, Hans J. |
| author_variant | h j i hj hji l b lb k h kh |
| building | Verbundindex |
| bvnumber | BV010432237 |
| ctrlnum | (OCoLC)39143446 (DE-599)BVBBV010432237 |
| edition | 3. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV010432237</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19960102</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">951002s1995 gw a||| |||| 00||| ger d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">945677367</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3886035395</subfield><subfield code="c">Pb. : DM 39.00, sfr 39.00, S 305.00</subfield><subfield code="9">3-88603-539-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)39143446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010432237</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Illiger, Hans J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug interactions in the therapy of malignant diseases</subfield><subfield code="c">H. J. Illiger ; L. Bornmann ; K. Herdrich</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">München [u.a.]</subfield><subfield code="b">Zuckschwerdt</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XLIII, 160 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Dt. Ausg. u.d.T.: Illiger, Hans J.: Arzneimittelinteraktionen bei der Therapie maligner Erkrankungen</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chimiothérapie - Complications</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Chimiothérapie - Effets indésirables</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Interactions médicamenteuses - Manuel</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs - Chimiothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Interactions</subfield><subfield code="v">handbooks</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Therapy</subfield><subfield code="x">adverse effects</subfield><subfield code="v">handbooks</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield><subfield code="v">handbooks</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapeutikum</subfield><subfield code="0">(DE-588)4009895-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Chemotherapeutikum</subfield><subfield code="0">(DE-588)4009895-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="4" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="2"><subfield code="a">Arzneimittelwechselwirkung</subfield><subfield code="0">(DE-588)4003147-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bornmann, Lothar</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herdrich, Klaus</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006951952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006951952</subfield></datafield></record></collection> |
| id | DE-604.BV010432237 |
| illustrated | Illustrated |
| indexdate | 2024-08-16T01:29:53Z |
| institution | BVB |
| isbn | 3886035395 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006951952 |
| oclc_num | 39143446 |
| open_access_boolean | |
| owner | DE-12 DE-19 DE-BY-UBM |
| owner_facet | DE-12 DE-19 DE-BY-UBM |
| physical | XLIII, 160 S. Ill. |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Zuckschwerdt |
| record_format | marc |
| spelling | Illiger, Hans J. Verfasser aut Drug interactions in the therapy of malignant diseases H. J. Illiger ; L. Bornmann ; K. Herdrich 3. ed. München [u.a.] Zuckschwerdt 1995 XLIII, 160 S. Ill. txt rdacontent n rdamedia nc rdacarrier Dt. Ausg. u.d.T.: Illiger, Hans J.: Arzneimittelinteraktionen bei der Therapie maligner Erkrankungen Chimiothérapie - Complications ram Chimiothérapie - Effets indésirables Interactions médicamenteuses - Manuel Tumeurs - Chimiothérapie Drug Interactions handbooks Drug Therapy adverse effects handbooks Neoplasms drug therapy handbooks Pharmakokinetik (DE-588)4115557-9 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Chemotherapeutikum (DE-588)4009895-3 gnd rswk-swf Arzneimittelwechselwirkung (DE-588)4003147-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Chemotherapie (DE-588)4127083-6 s Pharmakokinetik (DE-588)4115557-9 s DE-604 Chemotherapeutikum (DE-588)4009895-3 s Arzneimittelwechselwirkung (DE-588)4003147-0 s Pharmakotherapie (DE-588)4076066-2 s Cytostatikum (DE-588)4068347-3 s Therapie (DE-588)4059798-2 s 1\p DE-604 Bornmann, Lothar Verfasser aut Herdrich, Klaus Verfasser aut DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006951952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Illiger, Hans J. Bornmann, Lothar Herdrich, Klaus Drug interactions in the therapy of malignant diseases Chimiothérapie - Complications ram Chimiothérapie - Effets indésirables Interactions médicamenteuses - Manuel Tumeurs - Chimiothérapie Drug Interactions handbooks Drug Therapy adverse effects handbooks Neoplasms drug therapy handbooks Pharmakokinetik (DE-588)4115557-9 gnd Cytostatikum (DE-588)4068347-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd Chemotherapeutikum (DE-588)4009895-3 gnd Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd |
| subject_GND | (DE-588)4115557-9 (DE-588)4068347-3 (DE-588)4076066-2 (DE-588)4059798-2 (DE-588)4009895-3 (DE-588)4003147-0 (DE-588)4073781-0 (DE-588)4127083-6 |
| title | Drug interactions in the therapy of malignant diseases |
| title_auth | Drug interactions in the therapy of malignant diseases |
| title_exact_search | Drug interactions in the therapy of malignant diseases |
| title_full | Drug interactions in the therapy of malignant diseases H. J. Illiger ; L. Bornmann ; K. Herdrich |
| title_fullStr | Drug interactions in the therapy of malignant diseases H. J. Illiger ; L. Bornmann ; K. Herdrich |
| title_full_unstemmed | Drug interactions in the therapy of malignant diseases H. J. Illiger ; L. Bornmann ; K. Herdrich |
| title_short | Drug interactions in the therapy of malignant diseases |
| title_sort | drug interactions in the therapy of malignant diseases |
| topic | Chimiothérapie - Complications ram Chimiothérapie - Effets indésirables Interactions médicamenteuses - Manuel Tumeurs - Chimiothérapie Drug Interactions handbooks Drug Therapy adverse effects handbooks Neoplasms drug therapy handbooks Pharmakokinetik (DE-588)4115557-9 gnd Cytostatikum (DE-588)4068347-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd Therapie (DE-588)4059798-2 gnd Chemotherapeutikum (DE-588)4009895-3 gnd Arzneimittelwechselwirkung (DE-588)4003147-0 gnd Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd |
| topic_facet | Chimiothérapie - Complications Chimiothérapie - Effets indésirables Interactions médicamenteuses - Manuel Tumeurs - Chimiothérapie Drug Interactions handbooks Drug Therapy adverse effects handbooks Neoplasms drug therapy handbooks Pharmakokinetik Cytostatikum Pharmakotherapie Therapie Chemotherapeutikum Arzneimittelwechselwirkung Krebs Medizin Chemotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006951952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT illigerhansj druginteractionsinthetherapyofmalignantdiseases AT bornmannlothar druginteractionsinthetherapyofmalignantdiseases AT herdrichklaus druginteractionsinthetherapyofmalignantdiseases |